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Abstract The number of older adults living with human
immunodeficiency virus (HIV) infection is growing and this
subpopulation of the epidemic is at heightened risk for a
variety of poor health outcomes including HIV-associated
neurocognitive disorders. The current study sought to exam-
ine the factors associated with freedom from neurocognitive
impairmentinolderHIV-infectedadults.Participantsincluded
74 middle-aged and older (mean age 51 years), HIV-infected
individuals with a mean estimated duration of infection of
17 years who underwent comprehensive neuropsychological,
psychiatric, and medical evaluations. Successful cognitive
aging (SCA) was operationally defined as the absence of
neurocognitive deficits as determined by a battery of well-
validated cognitive tests and self-endorsed cognitive com-
plaints. Thirty-two percent of the cohort met these criteria.
Compared to the group that did not meet these criteria,
successful cognitive agers had significantly lower lifetime
rates of major depressive disorder and current affective
distress (e.g., depression, anxiety). Moreover, the SCA group
evidenced better everyday functioning outcomes, including
medication adherence, lower self-reported rates of declines in
activities of daily living, and superior abilities related to
medication management and dealing with healthcare pro-
viders. SCA was not related to demographic composition,
HIV disease or treatment factors, medical comorbidities, or
histories of substance use disorders. Findings from this
preliminary study suggest that approximately one-third of
older persons with HIV were free of cognitive impairments,
which is associated with more favorable emotional, psycho-
social, and everyday functioning.
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The growth of the population aged 60 or over is currently
more than twice the growth rate of the total world
population (2.6% and 1.2%, respectively; Department of
Economic and Social Affairs Population Division 2009),
and an increasing number of these individuals are infected
with human immunodeficiency virus (HIV). The successful
introduction of combination antiretroviral therapies (cART)
in the mid-1990s has contributed to a significant decline in
the mortality associated with HIV and acquired immuno-
deficiency syndrome (AIDS). More than one-quarter of
people living with HIV/AIDS in the USA are now over the
age of 50, which represents more than a 60% increase from
2001 (CDC 2008b). In addition, individuals over the age of
50 account for 15% of incident cases of HIV (CDC 2008a).
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DOI 10.1007/s13365-010-0008-zBy the year 2015, it is estimated that more than half of the
HIV/AIDS population in the USA will be over 50 years old
(Smith 2006). Given the rapid growth of this population, it
is becoming increasingly important to understand the risk
and protective factors relevant to aging with HIV.
Older individuals face a variety of unique medical risks
and challenges pertaining to HIV infection. For example,
older HIV-infected adults are at greater risk of more rapid
disease progression (e.g., Phillips et al. 1991) and mortality
(e.g., CDC 2008b; Egger et al. 2002), likely due to a variety
of factors, including delayed diagnosis and medical care
(Bamford et al. 2010), immune downregulation (e.g.,
Gardner 1980), and diminished and delayed immunologic
reconstitution with cART. There is also a higher prevalence
of comorbidities among older adults with HIV such as
hypertension, hypertriglyceridemia, low bone mineral den-
sity, frailty, and lipodystrophy (Onen et al. 2010).
The central nervous system (CNS) is also vulnerable to the
combined effects of age-related changes and HIV. Older HIV-
infected adults may show disproportionate changes in brain
structure (e.g., Ernst and Chang 2004;J e r n i g a ne ta l .2005)
and function (e.g., Larussa et al. 2006; Valcour et al. 2004),
although research on this issue is not conclusive (e.g., Scott
et al. in press). The prevalence of HIV-associated neuro-
cognitive disorders (HAND), including HIV-associated
dementia (HAD), tends to be higher in older adults (Becker
et al. 2004; Valcour et al. 2004). For example, Valcour and
colleagues (2004) found that, even after controlling for
important confounding variables, older HIV-infected persons
were three times more likely to be diagnosed with HAD than
younger patients. Consistent with the primary effects of HIV
on white matter and the frontostriatal circuits, older adults
with HIV evidence neurocognitive impairment compared to
healthy comparison subjects on measures of executive
functions, episodic memory, and information processing
speed (e.g., Cherner et al. 2004; Sacktor et al. 2007). In
regard to functional implications of such deficits in this
population, neurocognitive impairments relate to worse
everyday functioning outcomes (e.g., Thames et al. in press),
including adherence to antiretrovirals (ARV; Hinkin et al.
2004), among older HIV-infected adults. Possible risk factors
for HAND among older adults include advanced HIV
disease (e.g., Cherner et al. 2004; Woods et al. 2010),
substance abuse (e.g., Becker et al. 2004), and cardiovascu-
lar disease (e.g., Becker et al. 2009; Foley et al. 2010).
Despite the convergence of CNS risk factors imposed by
aging and HIV, there is considerable heterogeneity in out-
comes such that some older HIV-infected adults avoid
cognitive morbidity (e.g., Cole et al. 2007). Indeed, while
the existing literature is largely focused on a “deficit
approach,” understanding the characteristics of older individ-
uals with HIV who are “aging successfully” (e.g., free from
actualandperceivedcognitiveimpairment)mayhelptoinform
preventative efforts. Although there is no single consensus
definition of successful aging (see Depp and Jeste 2006 for a
review), a number of recent reports have focused on
successful cognitive aging (SCA Depp et al. 2010; Fiocco
and Yaffe 2010). SCA broadly refers to the multidetermined
process of preserving cognitive abilities, or exhibiting less-
than-expected decline in neural structure and function
typically associated with aging and its comorbidities. Re-
search, to date, suggests that SCA is associated with higher
levels of cognitive and brain reserve (e.g., Stern 2003), which
may be due to developing cognitive resources earlier in life
(e.g., education) or from neurobehavioral adaptations later in
life. Predictors of SCA include psychosocial factors such as
resilience to stressors (Lamond et al. 2008), freedom from
syndromal or subsyndromal depression (Vahia et al. 2009),
social support (Daffner 2010), and healthy lifestyle behaviors
(e.g., diet and exercise; Daffner 2010; Yaffe et al. 2009).
Importantly, many of the emerging predictive factors of SCA,
such as exercise and smoking, can be modified by behavioral
change and therefore possibly promote SCA (e.g., Aguero-
Torres et al. 2001; Tomaszewski Farias et al. 2009).
Little research has been devoted to studying cognitive
function in older HIV-infected adults, and to our knowledge,
no studies have investigated SCA in this growing subpopu-
lation of the HIVepidemic. Thus, the aim of our study was to
determine the prevalence, predictors (i.e., demographic,
psychiatric, and medical), and functional outcomes of SCA
in a modest sample of older persons living with HIV. Given
the separate HIVand SCA literatures reviewed above, it was
hypothesized that SCA would be associated with higher
cognitive reserve (e.g., education), lower rates of depression,
lesssevereHIVdisease,andbetterpsychosocialandeveryday
functioning outcomes (e.g., medication adherence).
Method
Participants
The study sample consisted of 74 individuals selected from
a larger National Institute of Mental Health (NIMH)-funded
study of HIV and memory (see Woods et al. 2009).
Participants were recruited from the general community
and local HIV treatment clinics. Inclusion criteria for the
current study were: (1) positive HIV serostatus as deter-
mined by enzyme-linked immunoabsorbent assays and
confirmatory Western blot analyses; (2) ≥45 years of age
at the time of evaluation; and (3) estimated duration of HIV
infection of ≥5 years. Although the age cutoff of 45 years is
younger than that generally used for studies on cognitive
aging, it is broadly consistent with previous studies
examining aging with HIV infection (e.g., Kissel et al.
2005; Lopardo et al. 2009) and with the demographic
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Participants who demonstrated severe psychiatric (e.g.,
schizophrenia), neurological (e.g., seizure disorders, stroke,
closed head injuries with loss of consciousness greater than
15 min, non-HAD, CNS neoplasms, or opportunistic
infections), or general medical (e.g., advanced liver disease
or other organ systems failures) conditions that might
impact cognition were excluded from the study. Estimated
verbal IQ less than 70 (based on the Wechsler Test of Adult
Reading; Psychological Corporation 2001), substance de-
pendence within 6 months of study participation, or a urine
toxicology screen-positive for illicit drugs (other than
marijuana) on the day of study participation were also a
basis for exclusion.
Successful cognitive aging
Although there is no universally agreed upon approach to
operationalizing SCA in clinical populations (Depp and
Jeste 2006; Fiocco and Yaffe 2010), we used a modified
method from neuroAIDS research (e.g., Antinori et al.
2007) that was adapted for the current research question.
This operational definition includes both objective and
subjective components, as in previous approaches to
delineating successful aging (Montross et al. 2006) and in
the determination of functional decline in the widely used
research criteria forHAND (Antinori et al. 2007). Specifically,
we defined our independent variable, SCA, based on
participants’ performance on a comprehensive, well-
validated battery of neurocognitive tests and a self-report
questionnaire of cognitive complaints. In brief, to be
classified in the SCA group, participants must have demon-
strated: (1) within normal limits scores (i.e., clinical domain
ratings <5, which correspond to >1 standard deviation below
the normative mean described below) on all seven of
the performance-based neurocognitive domains assessed;
and (2) within normal limits scores (i.e., <1 standard
deviation above the normative mean) on the Confusion–
Bewilderment subscale of the Profile of Mood States
(POMS; McNair et al. 1981). In the current study sample,
the POMS Confusion–Bewilderment scale correlated
significantly with clinical ratings of executive functions
(Spearman’s ρ=0.31, p=0.008) and speed of information
processing (Spearman’s ρ=0.25, p=0.03) and was signif-
icantly associated with impairment on the HIV dementia
scale using the Morgan et al. (2008) normative standards
(X
2=4.2, p=0.04).
Materials and procedure
After providing written, informed consent, participants
completed a comprehensive neuropsychological, psychi-
atric, and medical research evaluation, which had been
approved by the University of California, San Diego
(UCSD) Human Research Protection Program.
Neurocognitive assessment
All participants completed a standardized battery of neuro-
cognitive tests designed in accordance with NIMH recom-
mendations to evaluate the cognitive domains most
commonly impaired with HIV infection (Antinori et al.
2007), including motor skills, executive functions, atten-
tion/working memory, episodic learning, episodic memory,
verbal fluency, and information processing speed. The
reader is referred to Woods et al. (2008b) for information
regarding the neurocognitive battery and to Woods et al.
(2004) for details about the well-validated blinded clinical
ratings procedures.
Psychiatric assessment
The POMS, which was used in our operationalization of
SCA, is a 65-item, self-report evaluation of current
moods states, was used to assess cognitive complaints
and acute affective distress (McNair et al. 1981). The
POMS instructs participants to rate various adjectives (e.g.,
“sluggish”) on a five-point Likert-type scale ranging from 0
(“not at all”)t o4( “extremely”) based on their mood during
the week prior to evaluation. POMS items correspond to six
subscales (e.g., confusion–bewilderment) that comprise a
total mood score in which higher scores indicate greater
distress. Raw scores were converted to demographically
adjusted Z-scores using published normative standards
(Nyenhuis et al. 1999). Each participant also received a
structured psychiatric assessment in which the Composite
International Diagnostic Interview (CIDI version 2.1;
World Health Organization 1998) was used to measure
lifetime and current (i.e., within 1 month of evaluation)
diagnoses of major depressive disorder (MDD), generalized
anxiety disorder (GAD), and substance-related disorders
according to Diagnostic and Statistical Manual of Mental
Disorders (4th edn.; American Psychiatric Association 1994)
standards.
Medical assessment
All participants underwent a full neuromedical evaluation,
which consisted of a thorough assessment of medications,
medical history, and current symptoms, a complete physical
and neurological evaluation, Centers for Disease Control
(CDC) staging, lumbar puncture, and blood draw. Reverse
transcriptase-polymerase chain reaction (RT-PCR; Amplicor,
Roche Diagnostics, Indianapolis, IN) was used to measure
levels of HIV ribonucleic acid (RNA) in plasma and
cerebrospinal fluid.
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Activities of daily living Participants’ self-reported ability to
perform activities of daily living (ADL was measured by a
modified version of the Lawton and Brody (1969) ADL scale,
which included 13 items assessing current and best prior
levels of functioning (e.g., financial and medication manage-
ment). Participants were classified as ADL dependent if they
demonstrated current decline from best to now in two or
more categories (see Heaton et al. 2004; Woods et al. 2008a).
Socioeconomic status To assess participant socioeconomic
status (SES), the Hollingshead SES scale was used
(Hollingshead 1975). The Hollingshead SES scale takes
into account marital status, gender, education, and occupa-
tion. Employment status (i.e., full-time gainful employ-
ment) was assessed by a simple self-report question
embedded in the neurobehavioral interview. The overall
rate of full-time employment was 36%, which is generally
consistent with prior studies in the cART era (e.g., Burns et
al. 2006).
Beliefs related to medication adherence (BERMA) The
BERMA survey was used to evaluate each participant’s
medication management (McDonald-Miszczak et al. 2004).
Specifically, the BERMA questionnaire assesses three
domains of adherence-related beliefs: memory for medi-
cations, dealing with health professionals, and attitudes
about medications. The survey consists of 53 items, with 20
items dedicated to medication adherence (e.g., “I am less
efficient at adhering to my medication regimen than I used
to be”), 23 items for assessing participants’ relationship
with healthcare providers (e.g., “I have difficulty talking
openly with my physician”), and ten items addressing
attitudes concerning medications (e.g., “I am taking too
much medication for my medical conditions”). Participants
are instructed to rate each BERMA item on a five-point
Likert scale ranging from 1 (“strongly disagree”)t o5
(“strongly agree”). Note that several items necessitate
reverse scoring such that higher values reflect better
medication adherence.
Medication adherence ARV adherence was also directly
measured for a subset of the population (n=37) with the
medication event monitoring system (MEMS; Aprex,
Union City, CA). The MEMS procedure used in this study
is described in detail elsewhere (see Woods et al. 2009). In
short, participants took their ARV medication for 4 weeks
from a pill bottle with a cap (Trackcap®) containing a
microchip device designed to record the time, date, and
frequency with which the participants opened their medi-
cation bottles. Adherence was recorded as percent of doses
taken as prescribed.
Statistical analyses
The study sample (SCA=24, Comparison=50) provided
sufficient statistical power (1-ß=0.89) to detect large univar-
iate and Chi-square between-group effect sizes (Erdfelder et
al. 1996). To examine differences between the SCA group
and Comparison group, paired t-tests (or their nonparametric
equivalents [e.g., Wilcoxon rank sums test] for non-normally
distributed variables) were used for continuous variables and
the Chi-square statistic was used for categorical variables.
For continuous variables, we also generated estimates of
effect size using the Cohen’s d statistic.
Results
Based on our study criteria, 24 out of the 74 HIV-infected
participants (32%) were classified as exhibiting SCA. The
SCAgrouphada medianglobalclinicalneurocognitiverating
of 3 (interquartile range [IQR]=2, 3), whereas the median in
the comparison group was 4 (IQR=4, 5.3; p<0.01). The
median POMS confusion/bewilderment Z-scores of the SCA
and comparison groups were −0.63 (IQR=−1.1, −0.2)
a n d0 . 5 8( I Q R = −0.2, 1.6), respectively (p<0.01). As
s h o w ni nT a b l e1, the SCA and comparison groups did not
differ significantly in age, sex, or ethnic identity (all p
values>0.10). Similarly, there were no between-groups
differences in any of our measures of cognitive reserve,
including years of education, WTAR estimated verbal IQ,
and the Hollingshead score (all p values>0.10).
Table 1 alsoshows thatindividuals in the SCA group were
significantlylesslikelytohavehadMDDduringtheirlifetime
(p<0.05). The prevalence of lifetime MDD in the SCA
group (33%) was less than half that which was observed in
the comparison sample (70%). A post hoc logistic regression
revealed that lifetime MDD predicted self-report SCA as
measured by the POMS (p=0.03), but not performance-
based SCA as measured by the clinical ratings of neuro-
cognitive deficits (p=0.20). Individuals in the SCA group
didnotdifferfromthoseinthecomparisongroupinlikelihood
of current major depressive, lifetime generalized anxiety, or
substance dependence disorders (all p values>0.10). No
study participants in either group demonstrated current
generalized anxiety disorder. In terms of current affec-
tive distress, however, individuals in the SCA group
endorsedsignificantlylowerscoresonthePOMSsubscalesof
tension-anxiety, depression-dejection, anger-hostility, and
fatigue-inertia (all p values<0.05), as well as higher POMS
vigor-activation scores (p<0.05).
Contrary to our study hypotheses, the two groups did not
differ in any measures of HIV disease severity or treatment
including years of HIV infection, AIDS diagnosis, cART
status, nadir and current CD4 counts, or HIV RNA in plasma
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also no between-group differences observed in any other
medical characteristics including hepatitis C co-infection,
hypertension, hypercholesterolemia, or type II diabetes melli-
tus (all p values>0.10). These data are displayed in Table 2.
Finally, we were interested in determining whether SCA
was associated with any advantages in daily functioning
(see Table 3). Results showed that SCA was significantly
associated with better self-reported medication management
as measured by the BERMA (p<0.05), as well as better
ARV adherence as measured by a 30-day behavioral
assessment using MEMS caps (p<0.05). The SCA and
comparison groups did not differ in their attitudes about
medications (p>0.10). There was no difference between the
two groups in employment status (p>0.10), but individuals
in the SCA group reported significantly greater comfort in
dealing with healthcare professionals and lower rates of
ADL dependence (p values<0.05).
HIV+SCA (n=24) HIV+comparison (n=50) p Values Cohen’s d
M(SD) or%
Demographic characteristics
Age (years) 52.1 (6.6) 50.9 (5.1) 0.416 0.21
Sex (female) 8.3% 12.0% 1.000
Ethnicity (Caucasian) 62.5% 66.0% 0.768
Cognitive reserve
Education (years) 13.3 (3.1) 13.9 (2.3) 0.366 −0.23
WTAR verbal IQ 104.5 (12.8) 102.9 (11.4) 0.610 0.13
Hollingshead score 36.6 (13.5) 34.8 (13.5) 0.590 0.13
Psychopathology
Major depressive disorder
Current 4.2% 14.0% 0.262
Lifetime 33.3% 70.0% 0.003
Generalized anxiety
Current 0% 0% N/A
Lifetime 8.3% 4.0% 0.591
Substance dependence 45.8% 58.0% 0.326
Profile of mood states
Tension/anxiety 6.2 (4.6) 8.8 (6.2) 0.046 −0.45
Depression/dejection 4.7 (5.8) 9.6 (10.8) 0.013 −0.51
Anger/hostility 3.4 (4.0) 6.5 (7.0) 0.023 −0.50
Vigor/activation 19.4 (6.9) 14.3 (6.4) 0.004 0.77
Fatigue/inertia 5.4 (5.4) 8.8 (7.1) 0.030 −0.51
Table 1 Demographic and
psychiatric characteristics of the
study samples
SCA Successful cognitive aging,
WTAR Wechsler Test of Adult
Reading.
HIV+SCA (n=24) HIV+comparison (n=50) p Values Cohen’s d
HIV disease characteristics
Duration of infection (years) 18.5 (5.9) 15.9 (6.6) 0.177 0.40
AIDS (%) 79.2 68.0 0.413 –
cART (%) 91.7 76 0.127 –
Nadir CD4 (cells/μl) 127.9 (112.9) 172.0 (203.1) 0.926 −0.24
Current CD4 (cells/μl) 502.4 (261.8) 544.8 (328.6) 0.698 −0.14
Plasma HIV RNA (% det.) 29.2 30.0 0.941 –
CSF HIV RNA (% det.) 15.0 19.4 0.688 –
Other medical characteristics
Hepatitis C 21.7% 22.9% 1.000 –
Hypertension 16.7% 18.0% 1.000 –
Hypercholesterolemia 0% 8.0% 0.297 –
Diabetes mellitus 8.3% 6.0% 0.657 –
Table 2 HIV disease and
medical characteristics of the
study samples
cART Combined antiretroviral
therapy, SCA successful
cognitive aging
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To our knowledge, this is the first study to examine the
prevalence, correlates, and everyday functioning outcomes
of SCA in older adults living with HIV infection, who are a
growing subpopulation of the HIV epidemic that is at risk
for considerable medical and psychological morbidity,
including HAND. We observed a 32% prevalence of SCA
in this HIV+ cohort, which was defined as the absence of
neurocognitive impairment across seven functional domains
as measured by both performance-based tests and self-
report of cognitive difficulties in daily life. These data
indicate that approximately one-third of older adults with
HIVare able to evade even mild forms of neuropsychological
impairment. Findings converge with those of Cole and
colleagues (2007), who reported that psychomotor skills
were preserved in long-term, asymptomatic HIV+ survivors.
It is notable that the rate of freedom from cognitive
impairment in this study was similar to that seen in samples
of older adults with a much older mean age (Montross et al.
2006; Yaffe et al. 2010). Thus, while a minority of patients
with HIVare able to retain cognitive functions across a wide
variety of domains in rates similar to seronegatives, these
data raise questions about whether prevalence rates of SCA
in HIV will decline as the population ages.
Contrary to our study hypotheses, results revealed no
associations between SCA and cognitive reserve or HIV
disease severity. Cognitive reserve has been linked to SCA
in healthy populations (Yaffe et al. 2009) and also has been
shown to negatively predict neuropsychological perfor-
mance in younger HIV populations (e.g., Basso and
Bornstein 2000; Stern et al. 1996). That cognitive reserve
did not predict SCA in our older HIV+ cohort was thus
unexpected, and may reflect the limitations of our relatively
small samples, cross-sectional study design, and use of both
self-report and performance-based neurocognitive indica-
tors of SCA. Inclusion of biological measures of brain
reserve (e.g., morphometry or diffusion tensor imaging)
might be also be more sensitive to SCA in older HIV-
infected populations (e.g., Sumowski et al. 2009). Relatedly,
it was surprising that none of the HIV disease severity or
treatment characteristics we measured were predictive of
SCA. It is possible that the relative immune health of our
sample (e.g., median current CD4>500 cells/μl) may have
precluded detection of differences between the two groups. It
is also possible that the current clinical HIV disease variables
reported herein are not as strongly associated with cognitive
functioning in the cART era (e.g., Sevigny et al. 2004). As
such, prospective studies informed by current models of the
neuropathogenesis of HAND might examine such neuro-
protective factors as brain-derived neurotrophic factor,
fibroblast growth factors, and erythropoietin might be
considered (e.g., Mocchetti et al. 2008).
Shifting our focus now to the psychiatric correlates of
SCA, HIV+ individuals with SCA were significantly less
likely to meet lifetime diagnostic criteria for MDD and
endorsed an overall lower severity of current affective
distress, including depression and anxiety during their lives,
which is in agreement with much of the general SCA
literature. The prevalence of lifetime MDD in the SCA
group (33%) was less than half that which was observed in
the comparison sample (70%). Studies of healthy, high-
functioning older individuals reliably implicate depression
as a risk factor for cognitive decline (e.g., Chodosh et al.
2007; Yaffe et al. 2009). Within the neuroAIDS literature,
depression is strongly related to elevated cognitive com-
plaints (e.g., Rourke et al. 1999); however, it is not
typically associated with the prevalence or incidence of
HAND (e.g., Cysique et al. 2007), regardless of the
etiology of MDD (e.g., primary). For example, Cysique
and colleagues (2007) found that neither lifetime nor
incident MDD was associated with performance on a
comprehensive battery of cognitive tests in an HIV+
sample. However, these were younger adults, perhaps it
takes time for the effects of depression to alter cognitive
trajectories. Interestingly, a post hoc analysis within the
Table 3 Psychosocial and functional characteristics of the study samples
HIV+SCA (n=24) HIV+comparison (n=50) p Values Cohen’s d
Berma
Memory for medications 82.8 (11.5) 73.4 (12.7) 0.002 0.75
Dealing with health professionals 99.2 (13.2) 91.3 (14.1) 0.022 0.57
Attitudes about medications 37.3 (6.9) 35.5 (5.9) 0.272 0.29
ADL dependence (%) 12.5% 40.8% 0.017 –
Unemployed (%) 65% 67% 0.851 –
MEMS ART adherence
a 97.5 (6.2) 89.9 (17.2) 0.036 0.55
ART Antiretroviral therapy, BERMA beliefs related to medication adherence, MEMS medication event monitoring system, SCA successful
cognitive aging
an=16 for HIV+SCA and n=21 for HIV+comparison group
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notion by revealing that lifetime MDD predicted self-report
SCA, but not performance-based SCA. Thus, our results
converge with the existing literature on depression and
HAND by suggesting that individuals without histories of
depression are less likely to report having experienced
neurocognitive declines.
Although the rates of current MDD did not differ
between groups, the SCA group reported higher levels of
vigor and lower levels of anxiety, dejection, anger, and
fatigue than the comparison group. These results suggest
that acute affective distress is negatively associated with
SCA, likely as a function of its correspondence with
neurocognitive complaints. One possible interpretation of
this finding is that the SCA group was better able to avoid
the negative effects of stress on perceived cognitive
problems, perhaps by way of resilience. Still, it should be
noted that we used participants’ scores on one POMS
subscale (i.e., confusion/bewilderment) to classify partici-
pants into the SCA group. Although there is no direct item
overlap between this POMS subscale and other POMS
subscales (and thus no true criterion contamination), it may
be expected that responses in one POMS domain will
correlate strongly with responses in the other five domains.
Indeed, the average interscale intercorrelation in this sample
was 0.60 (range=−0.45 to 0.70). Future studies of SCA in
HIV-infected populations would benefit from inclusion of
more independent measures of cognitive complaints (e.g.,
Patient’s Assessment of Own Functioning Inventory; Rourke
et al. 1999). Additionally, it may be useful to investigate
other aspects of mood and affect, such as apathy, in the
context of SCA in HIV infection (Hoare et al. 2010;P a u le t
al. 2005).
The most consistent finding from this study was that SCA
was associated with a variety of beneficial everyday func-
tioning outcomes. These findings extend the literature on
HIV-associated neurocognitive impairment and everyday
functioning by focusing on SCA (see Marcotte and Grant
2010). Individuals in the SCA group were nearly fivefold
less likely to report ADL dependence than persons in the
comparison group. SCA was also associated with superior
medication management abilities, as measured by generic
self-report (i.e., BERMA) and a behavioral index of cART
adherence (i.e., MEMS). These findings were associated
with medium effect sizes and are consistent with prior
literature suggesting that HIV-associated neurocognitive
impairment, especially in the domains of executive functions
and episodic memory, increases the likelihood of non-
adherence (e.g., Hinkin et al. 2002). Although in general,
older age has been associated with better medication
adherence among HIV-infected individuals (e.g., Ettenhofer
et al. 2009), it also has been shown that neurocognitive
impairment increases the risk of poor medication adherence
in older HIV patients (Hinkin et al. 2004). The directionality
of the relationship, however, is unclear since it is not only
possible that SCA allows HIV-infected individuals to
maintain their functional independence, but also that those
HIV patients who continue to perform ADLs, in particular
adherence, may be more likely to achieve successful
cognitive outcomes (e.g., Ettenhofer et al. 2010). Regardless,
maintaining independence in functional activities is an
important goal for a chronic medical condition, such as
HIV, as functional dependence has been shown to predict
mortality (e.g., Shen et al. 2005). Thus, understanding the
factors that contribute to independence in ADLs is crucial
and should be a focus of medical and psychological
intervention development, including strategies that might
promote SCA (e.g., cognitive enrichment).
We also found that HIV+ individuals with SCAwere more
likely to report better interactions with their healthcare
providers. Older HIV patients must interact with wide range
of healthcare professionals on a regular basis, and our results
support the importance of constructive interactions between
these caregivers and their older HIV-infected patients. There
are several potential explanations of our findings. First, it is
possible that those who are less impaired are able to
communicatemoreeffectivelywiththeirhealthcareproviders.
Further, it is also possible that those older HIV patients who
are more comfortable interacting with their healthcare
professionals are more likely to achieve successful cognitive
outcomes because these patients are more likely to openly
discuss their health needs and concerns with their healthcare
providers (although patterns of treatment were not different
between groups). Finally, older HIV patients may be more
likely to adhere to the instructions of healthcare providers in
whom they are most confident, resulting in better cognitive
outcomes in these patients. Given this range of possibilities,
future research should more closely examine the connection
between cognitive outcomes and older HIV patients’ dealings
with their healthcare providers. Such work may elucidate
aspects of relationships between healthcare providers and
older HIV patients essential for promoting SCA. If such
factors are determined, healthcare providers could potentially
promote SCA in their older HIV-infected patients simply by
altering the way in which they interact with these patients.
Theresultsofthisstudyshouldbeinterpretedinlightofthe
following limitations. First, the study sample size was
relatively small and thereby only allowed us to detect
medium-to-large effects. Second, the study used a cross-
sectional design, which did not permit the examination of
directionality of causal effects. Ideally, future HIV infection
would involve following neurocognitively normal, but at-risk
older individuals prior to seroconversion and throughout the
courseoftheirinfection.Third,ourstudydidnotincludeother
relevant predictors of SCA including psychosocial variables,
such as resilience (Lamond et al. 2008), spirituality (Vahia et
116 J. Neurovirol. (2011) 17:110–119al. in press) and wisdom (Blazer 2006), and health
behaviors, such as exercise and smoking (e.g., Yaffe et al.
2009). Thus, it will be important to confirm and extend the
results reported here using a prospective, longitudinal study
design that includes larger samples of HIV-infected (and
demographically comparable seronegative) older adults.
Such studies will help to identify important risk and
protective factors in regard to trajectories of cognitive aging,
which may facilitate the development of effective interven-
tions aimed at promoting SCA and better quality of life
among persons living with HIV infection.
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